Jian Wang , Tao Guo , Xiaomin Zhang , Jiacheng Guo , Xiangyu Meng , Shi Yan , Ye Wang , Yutian Xiao , Weidong Xu , Xuedong Wei , Keke Ding , Jun Zhang , Yuanyuan Mi , Sheng Wu , Jie Chen , Yuhua Huang , Shancheng Ren , Jianquan Hou
{"title":"全面研究 NCBP2 的致癌功能和免疫学作用,并验证其在前列腺癌中的作用。","authors":"Jian Wang , Tao Guo , Xiaomin Zhang , Jiacheng Guo , Xiangyu Meng , Shi Yan , Ye Wang , Yutian Xiao , Weidong Xu , Xuedong Wei , Keke Ding , Jun Zhang , Yuanyuan Mi , Sheng Wu , Jie Chen , Yuhua Huang , Shancheng Ren , Jianquan Hou","doi":"10.1016/j.tranon.2024.102049","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Nuclear cap-binding protein 2 (NCBP2), as the component of the cap-binding complex, participates in a number of biological processes, including pre-mRNA splicing, transcript export, translation regulation and other gene expression steps. However, the role of NCBP2 on the tumor cells and immune microenvironment remains unclear. To systematically analyze and validate functions of NCBP2, we performed a pan-cancer analysis using multiple approaches.</p></div><div><h3>Methods</h3><p>The data in this study were derived from sequencing, mutation, and methylation data in the TCGA cohort, normal sample sequencing data in the GTEx project, and cell line expression profile data in the CCLE database.</p></div><div><h3>Results</h3><p>Survival analyses including the Cox proportional-hazards model and log-rank test revealed the poor prognostic role of NCBP2 in multiple tumors. We further validated the oncogenic ability of NCBP2 in prostate cancer cell lines, organoids and tumor-bearing mice. A negative correlation was observed between NCBP2 expression and immune score by the ESTIMATE algorithm. Simultaneously, the NCBP2-induced immunosuppressive microenvironment might be related to the decline in CD8<sup>+</sup> <em>T</em> cells and the increase in regulatory T cells and neutrophils, examined by flow cytometry experiments for NCBP2 overexpressed tumor-bearing mice.</p></div><div><h3>Conclusion</h3><p>This research offered strong proof supporting NCBP2 as the prognostic marker and the therapeutic target in the future.</p></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":null,"pages":null},"PeriodicalIF":5.0000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523324001761/pdfft?md5=0971bc90c3fcda83dc0bb1001ecc0cac&pid=1-s2.0-S1936523324001761-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Comprehensive investigation in oncogenic functions and immunological roles of NCBP2 and its validation in prostate cancer\",\"authors\":\"Jian Wang , Tao Guo , Xiaomin Zhang , Jiacheng Guo , Xiangyu Meng , Shi Yan , Ye Wang , Yutian Xiao , Weidong Xu , Xuedong Wei , Keke Ding , Jun Zhang , Yuanyuan Mi , Sheng Wu , Jie Chen , Yuhua Huang , Shancheng Ren , Jianquan Hou\",\"doi\":\"10.1016/j.tranon.2024.102049\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Nuclear cap-binding protein 2 (NCBP2), as the component of the cap-binding complex, participates in a number of biological processes, including pre-mRNA splicing, transcript export, translation regulation and other gene expression steps. However, the role of NCBP2 on the tumor cells and immune microenvironment remains unclear. To systematically analyze and validate functions of NCBP2, we performed a pan-cancer analysis using multiple approaches.</p></div><div><h3>Methods</h3><p>The data in this study were derived from sequencing, mutation, and methylation data in the TCGA cohort, normal sample sequencing data in the GTEx project, and cell line expression profile data in the CCLE database.</p></div><div><h3>Results</h3><p>Survival analyses including the Cox proportional-hazards model and log-rank test revealed the poor prognostic role of NCBP2 in multiple tumors. We further validated the oncogenic ability of NCBP2 in prostate cancer cell lines, organoids and tumor-bearing mice. A negative correlation was observed between NCBP2 expression and immune score by the ESTIMATE algorithm. Simultaneously, the NCBP2-induced immunosuppressive microenvironment might be related to the decline in CD8<sup>+</sup> <em>T</em> cells and the increase in regulatory T cells and neutrophils, examined by flow cytometry experiments for NCBP2 overexpressed tumor-bearing mice.</p></div><div><h3>Conclusion</h3><p>This research offered strong proof supporting NCBP2 as the prognostic marker and the therapeutic target in the future.</p></div>\",\"PeriodicalId\":48975,\"journal\":{\"name\":\"Translational Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2024-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1936523324001761/pdfft?md5=0971bc90c3fcda83dc0bb1001ecc0cac&pid=1-s2.0-S1936523324001761-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1936523324001761\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523324001761","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Comprehensive investigation in oncogenic functions and immunological roles of NCBP2 and its validation in prostate cancer
Background
Nuclear cap-binding protein 2 (NCBP2), as the component of the cap-binding complex, participates in a number of biological processes, including pre-mRNA splicing, transcript export, translation regulation and other gene expression steps. However, the role of NCBP2 on the tumor cells and immune microenvironment remains unclear. To systematically analyze and validate functions of NCBP2, we performed a pan-cancer analysis using multiple approaches.
Methods
The data in this study were derived from sequencing, mutation, and methylation data in the TCGA cohort, normal sample sequencing data in the GTEx project, and cell line expression profile data in the CCLE database.
Results
Survival analyses including the Cox proportional-hazards model and log-rank test revealed the poor prognostic role of NCBP2 in multiple tumors. We further validated the oncogenic ability of NCBP2 in prostate cancer cell lines, organoids and tumor-bearing mice. A negative correlation was observed between NCBP2 expression and immune score by the ESTIMATE algorithm. Simultaneously, the NCBP2-induced immunosuppressive microenvironment might be related to the decline in CD8+T cells and the increase in regulatory T cells and neutrophils, examined by flow cytometry experiments for NCBP2 overexpressed tumor-bearing mice.
Conclusion
This research offered strong proof supporting NCBP2 as the prognostic marker and the therapeutic target in the future.
期刊介绍:
Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.